|
|
Volumn 341, Issue , 2010, Pages
|
|
New drugs should be judged on "willingness to pay" basis, says leading economist.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
PRESCRIPTION DRUG;
COST BENEFIT ANALYSIS;
DIABETES MELLITUS;
ECONOMICS;
HEALTH SERVICE;
HUMAN;
NOTE;
COST-BENEFIT ANALYSIS;
DIABETES MELLITUS;
HEALTH SERVICES NEEDS AND DEMAND;
HUMANS;
HYPOGLYCEMIC AGENTS;
PRESCRIPTION DRUGS;
|
|
EID: 77954998387
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.c3899 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
